Biological therapies in rheumatic diseases

Clinica Terapeutica

Volumn 164, Issue SUPPL.5, 2013, Pages

  Conti, F ^a   Ceccarelli, F ^a   Massaro, L ^a   Cipriano, E ^a   Di Franco, M ^a   Alessandri, C ^a   Spinelli, F R ^a   Scrivo, R ^a   Valesini, G ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Ankylosing s arthritis; Systemic lupus erythematosus

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR; ABATACEPT; ADALIMUMAB; ANTIRETROVIRUS AGENT; ATACICEPT; BELIMUMAB; CANAKINUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EPRATUZUMAB; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; RITUXIMAB; SIFALIMUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ANKYLOSING SPONDYLITIS; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; BIOLOGICAL THERAPY; CELL MATURATION; DRUG MECHANISM; MOLECULE; PATHOGENESIS; PROGNOSIS; PSORIATIC ARTHRITIS; REMISSION; REVIEW; RHEUMATIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; APLASTIC ANEMIA; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL DIFFERENTIATION; CELL SURVIVAL; CELLULITIS; CINCA SYNDROME; DIARRHEA; DISEASE ACTIVITY; DRUG HALF LIFE; DRUG INDICATION; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FATIGUE; HEADACHE; HERPES ZOSTER; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPERTENSION; HYPOTENSION; IMMUNE RESPONSE; INTESTINE PERFORATION; JUVENILE RHEUMATOID ARTHRITIS; LONG TERM SURVIVAL; MUCKLE WELLS SYNDROME; NAUSEA; NEUTROPENIA; OFF LABEL DRUG USE; PANCYTOPENIA; PHARYNGITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; SPONDYLARTHRITIS; T LYMPHOCYTE ACTIVATION; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VASCULITIS; WOUND HEALING IMPAIRMENT;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTE SUBSETS; BIOLOGICAL THERAPY; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERFERONS; INTERLEUKIN-1; INTERLEUKIN-6; LYMPHOCYTE DEPLETION; MULTICENTER STUDIES AS TOPIC; OFF-LABEL USE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84888103680     PISSN: 00099074     EISSN: 19726007     Source Type: Journal    
DOI: 10.7417/CT.2013.1622     Document Type: Review

References (167)

1. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-7
2. Boulianne GL, Hozumi N, Shulman MJ. Production of functional chimaeric mouse/human antibody. Nature 1984; 312:643-6
3. Ternant D, Paintaud G. Pharmacokinetics and concentrationeffect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther 2005; 5:37-47
4. Garrison L, McDonnell ND. Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis 1999; 58, Suppl 1: 165-169
5. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor α agents. Inflamm Bowel Dis 2007;13:1323-32
6. Nesbitt A, Fossati G, Brown D, et al. Effect of structure of conventional anti-TNFs and certolizumab pegol on mode of action in rheumatoid arthritis. Ann Rheum Dis 2007; 66, Suppl 2: 296
7. Chan FK-M, Chun HJ, Zheng L, et al. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000; 288:2351-4
8. Marra CA, Bansback N, Anis AH, et al. Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis. Clin Rheumatol 2011; 30:9-18
9. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117:244-79
10. Valesini G, Iannuccelli C, Marocchi E, et al. Biological and clinical effects of anti TNFα treatment. Autoimmun Rev 2007; 7:35-41
11. Caporali R, Bobbio Pallavicini F, Filippini M, et al. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: A reappraisal. Autoimmun Rev 2008; 8:274-80
12. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008; 118:3537-45
13. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000; 51:289-98
14. Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999; 163:1521-8
15. Ulfgren AK, Andersson U, Engstrom M, et al. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum 2000; 43:2391-6
16. Pittoni V, Bombardieri M, Spinelli FR, et al. Anti-tumour necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab, selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13. Ann Rheum Dis 2002; 61:723-5
17. Catrina AI, Lampa J, Ernestam S, et al. Anti-tumour necrosis factor, (TNF) alpha therapy, etanercept. down-regulates serum matrix metalloproteinase, (MMP)3 and MMP-1 in rheumatoid arthritis. Rheumatol, Oxford 2002; 41:484-9
18. Klimiuk PA, Sierakowski S, Domyslawska I, et al. Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab. Arch Immunol Ther Exp, (Warsz) 2004; 52:36-42
19. Bugatti S, Caporali R, Manzo A, et al. Involvement of subchondral bone marrow in rheumatoid arthritis: lymphoid neogenesis and in situ relationship to subchondral bone marrow osteoclast recruitment. Arthritis Rheum 2005; 52:3448-59
20. Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004; 200:277-85
21. Seriolo B, Paolino S, Sulli A, et al. Bone Metabolism changes during anti-TNFα therapy in patients with active rheumatoid arthritis. Ann N Y Acad Sci 2006; 1069:420-7
22. Seriolo B, Paolino S, Sulli A, et al. Effects of anti-TNFα?treatment on lipid profile in patients with active rheumatoid arthritis. Ann NY Acad Sci 2006; 1069:414-9
23. Scirè CA, Montecucco C, Codullo V, et al. Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predict short-term cc. Rheumatology (Oxford) 2009; 48:1092-7
24. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis, (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008; 82:372:5
25. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment. Lancet 2004; 363:675-81
26. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2002; 6:1443-50
27. Maini R, St Clair EW, Lipsky, et al. Infliximab (chimeric anti-tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 1999; 354:1932-9
28. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50:3432-43
29. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48:35-45
30. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 1:26-37
31. Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009; 374:210-21
32. Keystone E, Genovese MC, Klareskog L, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis 2010; 69:1129-35
33. Keystone E, van der Heijde D, Mason D, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis. Arthritis Rheum 2008; 58:3319-29
34. Van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998; 41:1845-50
35. Caporali R, Conti F, Alivernini S, et al. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. Clin Exp Rheumatol 2011; 29:7-14
36. Bobbio Pallavicini F, Caporali R, Alpini C, et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis 2006; 66:302-307
37. Scrivo R, Conti F, Spinelli FR, et al. Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature. Reumatismo 2009; 61:107-117
38. Conti F, Scrivo R, Spinelli FR, et al. Outcome in patients with rheumatoid arthritis switching TNF-alpha antagonists: a single center, observational study over an 8-year period. Clin Exp Rheumatol 2009; 27:540-1
39. Keystone EC. Switching tumor necrosis factor inhibitors: an opinion. Nat Clin Pract Rheumatol 2006; 2:576-7
40. Chimenti MS, Graceffa D, Perricone R. Anti-TNFα discontinuation in rheumatoid and psoriatic arthritis: is it possible after disease remission? Autoimmun Rev 2011; 10:636-40
41. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359:1187-93
42. van der Heijde D, Dijkmans B, Geusens P et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52:582-591
43. Davis JC Jr, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2003; 48:3230-6
44. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebocontrolled trial. Arthritis Rheum 2006; 54:2136-46
45. Inman RD, Davis JC Jr, van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58:3402-12
46. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005; 52:1227-36
47. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356:385-90
48. Mease PJ, Gladmann DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52:3279-89
49. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009; 60:976-86
50. Salvarani C, Pipitone N, Marchesoni A, et al. Italian Society for Rheumatology. Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. Clin Exp Rheumatol 2011; 29:S28-41
51. Conti F, Ceccarelli F, Marocchi E et al. Switching tumor necrosis factor α antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over 5-year period. Ann Rheum Dis 2007; 66:1393-7
52. Braun J, Rudwaleit M, Kary S, et al. Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis. Rheumatology (Oxford) 2010; 49:1578-89
53. Braun J, van den Berg R, Baraliakos X et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70:896-904
54. Braun J, Baraliakos X, Listing J, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007; 57:639-47
55. Scrivo R, Spadaro A, Spinelli FR, et al. Uveitis following the use of tumor necrosis factor alpha inhibitors: comment on the article by Lim et al. Arthitis Rheum 2008; 58:1555-6
56. van der Heijde D, Schiff MH, Sieper J, et al. ATLAS Study Group. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: longterm results from the ATLAS trial. Ann Rheum Dis 2009; 68:922-9
57. Glintborg B, Ostergaard M, Krogh NS, et al. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010; 69:2002-8
58. Glintborg B, Ostergaard M, Krogh NS, et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 2013; 72:1149-55
59. Conti F, Priori R, Chimenti MS, et al. Successful treatment with intraarticular infliximab for resistant knee monarthritis in a patient with spondylarthropathy: a role for scintigraphy with 99mTc-infliximab. Arthritis Rheum 2005; 52:1224-6
60. Chianelli M, D'Alessandria C, Conti F, et al. New radiopharmaceuticals for imaging rheumatoid arthritis. Q J Nucl Med Mol Imaging 2006; 50:217-25
61. Conti F, Ceccarelli F, Priori R, et al. Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumor necrosis factor α. Ann Rheum Dis 2008; 67:1787-90
62. Conti F, Malviya G, Ceccarelli F, et al. Role of scintigraphy with 99mTc-infliximab in predicting the response of intraarticular infliximab treatment in patients with refractory monoarthritis. Eur J Nucl Med Mol Imaging 2012; 39:1339-47
63. Todoerti M, Pipitone N, Matucci-Cerinic M, et al. Recommendations for the use of biologic therapy from the Italian Society for Rheumatology: off-label use. Clin Exp Rheumatol 2011; Suppl 66:S42-62
64. Accorinti M, Pirraglia MP, Paroli MP, et al. Infliximab treatment for ocular and extraocular manifestations of Behcet's disease. Jpn J Ophthalmol 2007; 51:191-6
65. Bachmann F, Nast A, Sterry W, et al. Safety and efficacy of the tumor necrosis factor antagonists. Semin Cutan Med Surg 2010; 1:35-47
66. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumor necrosis factor agents and tuberculosis risk: mechanism of action and clinical management. Lancet Infect Dis 2003; 3:148-55
67. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this state-ment. Am J Respir Crit Care Med 2000; 161:S221-S247
68. Pai M, Menzies D. The new IGRA and the old TST. Making good use of disagreement. Am J Respir Crit Care Med 2007; 175:529-31
69. Scrivo R, Sauzullo I, Mengoni F, et al. Serial interferon-γ?release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents. Clin Rheumatol 2012; 31:1567-75
70. Favalli EG, Caporali R, Sinigaglia L, et al. Italian Society for Rheumatology. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety. Clin Exp Rheumatol 2011; 29, 66:15-27
71. Roux CH, Brocq O, Breuil V, et al. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) 2006; 45:1294-7
72. Ferri C, Ferraccioli G, Ferrari D, et al. Safety of anti-tumor necrosis factor-α therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 2008; 35:1944-9
73. Askling J, Raaschou P, van Vollenhoven R, et al. Anti TNF therapy and cancer risk: relation to duration of follow up, cumulative treatment, and therapeutic response. Ann Rheum Dis 2008; 67, Suppl 2:52
74. Asking J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64:1421-6
75. De Angelis F, Di Rocco A, Minotti C, et al. Atypical presentation of anaplastic large T-cell lymphoma mimicking an articular relapse of rheumatoid arthritis in a patient treated with etanercept. A case report and literature review. Leuk Res 2012; 36:e199-201
76. Dixon WG, Watson KD, Lunt M et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatol Biologics Register. Arthritis Rheum 2007; 56:2905-12
77. Westlake S, Colebatch AN, Baird J et al. Tumor necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatol, Oxford 2011; 50:518-531
78. Chung ES, Paker M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107:3133-3140
79. Bosch X, Saiz A, Ramos-Casalas M. and the BIOGEAS Study Group. Monoclonal antibody therapy-associated neurological disorders. Nat Rev Neurol 2011; 7:165-72
80. Harrison MJ, Dixon WG, Watson KD, et al. Rats of newonset psoriasis in patients with rheumatoid arthritis receiving anti-tumor necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009; 68:209-15
81. Sfikakis PP, Iliopoulos A, Elezoglou A, et al. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005; 52:2513-8
82. Alessandri C, Scrivo R, Spinelli FR, et al. Autoantibody production in anti-TNFα treated patients. Ann N Y Acad Sci 2007; 1110:319-29
83. Bendtzen K. Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies? Arthritis Rheum 2011; 63:867-70
84. Granowitz EV, Porat R, Mier JW et al. Pharmacokinetics, safety, and immnomodulatory effects of human recombinant interleukine-1 receptor antagonist in healthy humans. Cytokines 1992; 4:353-60
85. Church LD, McDermott MF. Canakinumab, a fully-human mAb against IL-1 beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther 2009;11:81-89
86. Bresnihan B. The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 2001; 30, 2:17-20
87. Moltó A, Olivé A. Anti IL-1 molecules: new comers and new indications. Joint Bone Spine 2010; 77:102-7
88. Dinarello Ca, Simon A, van der Meer JWM. Treating inflammation by blocking interleukine-1 in a broad spectrum of diseases. Nature Rev 2012; 11:633-52
89. Fleishmann RM, Schechtman J, Bennett R, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (rmetHulL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003; 48:927-34
90. Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology (Oxford) 2012; 51:38-47
91. Hibi M, Murakami M, Saito M, et al. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990; 63:1149-57
92. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis 2007; 66:1162-7
93. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study.: a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371:987-97
94. Grossman RM, Krueger J, Yourish D, et al. Interleukin-6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci U S A 1989; 86:6367-71
95. Jones G, Sebba A, Gu J et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010; 69:88-96
96. Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to metotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009; 19:12-19
97. Maini RN, Taylor PC, Kishimoto J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, Tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006; 6:2817-29
98. Navarro-Millán I, Singh JA, Curtis JR, et al. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther 2012; 34:788-802
99. Curtis J, Lanas A, Werther W, et al. Factors associated with upper and lower gastrointestinal perforation in a cohort of patients with rheumatoid arthritis. Arthritis Rheum 2009; 60:602
100. Gallucci RM, Simeonova PP, Matheson JM, et al. Impaired cutaneous wound healing in interleukin-6-deficient and immunosuppressed mice. FASEB J 2000; 14:2525-31
101. Östör AJK. Abatacept: a T-cell co- stimulation modulator for the treatment of rheumatoid arthritis. Clin Rheumatol 2008; 28:27:1343-53
102. Razmara M, Hilliard B, Ziarani AK, et al. CTLA4Ig converts naïve CD4+CD25- T cells into CD4+CD25+ regulatory T cells. International Immunol 2007; 20:471-83
103. Axmann R, Herman S, Zaiss M, et al. CTLA4 directly inhibits osteoclast formation. Ann Rheum Dis 2008; 67:1603-9
104. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355:1018-28
105. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005; 353:1114-23
106. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomized, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008; 67:1096-1103
107. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006; 144:865-76
108. Weinblatt M, Combe B, Covucci A, et al. Safety of the selective constimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 2006; 54:2807-16
109. Kremer JM, Westhovens R, Le Bars M, et al. Time to treatment response with abatacept in patients with rheumatoid arthritis and an inadequate response methotrexate. Arthritis Rheum 2008; 58:308-17
110. Schiff M, Reed DM, Kelly S, et al. Likelihood of maintain or increasing American college of rheumatology responses in biologic-naïve patients treated with abatacept plus methotrexate: insights from the AIM trial. Arthritis Rheum 2008; 58:546
111. Furst DE, Keystone EC, Braun J, et al. Update consensus statement on biological agents for the treatment of rheumatic diseases 2011. Ann Rheum Dis 2012; 71, Suppl 2:2-45
112. Khraishi M. Comparative overview of safety of the biologics in rheumatoid arthritis. J Rheumatol 2009; 82:25-32
113. Dörner T, Kinnman N, Tak PP. Targeting B cells in immunemediated inflammatory disease: a comprehensive review of mechanism of action and identification of biomarkers. Pharmacol Ther 2010; 125:464-75
114. Van Zeben D, Hazes JM, Zwinderman AH, et al. Clinical significance of rheumatoid factors in early rheumatoid arthritis results of a follow up study. Ann Rheum Dis 1992; 51:1029-35
115. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344:907-16
116. Anolik JH, Barnard J, Cappione A, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004; 50:3580-90
117. Odendahl M, Jacobi A, Hansen A, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000; 165:5970-79
118. Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomized, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate. [Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)]. Ann Rheum Dis 2010; 69:1629-35
119. Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011; 70:39-46
120. Rubbert-Roth A, Tak PP, Zerbini C, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study, MIRROR Rheumatol Oxford 2010; 49:1683-93
121. Mease PJ, Cohen S, Gaylis NB, et al. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol 2010; 5:917-27
122. Vital EM, Dass S, Rawstro AC, et al. Management of non response to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 2010;62:1273-9
123. Bunch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70:909-20
124. Finckh A, Ciurea A, Brulhart L, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumor necrosis factor (TNF. agents after previous failure of an anti-TNF agent? Ann Rheum Dis 2010; 69:387-93
125. Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum 2007; 56:2715-8
126. Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009; 61:482-7
127. Ramos-Casals M, Soto MJ, Cuadraro MJ, et al. Rituximab in systemic lupus erythematosus: a systematic review of offlabel use in 188 cases. Lupus 2009; 18:767-76
128. Priori R, Medda E, Conti F, et al. Familial autoimmunity as a risk factor for systemic lupus erythematosus and vice versa: a case-control study. Lupus 2003; 12:735-740
129. Alessandri C, Bombardieri M, Di Prospero L, et al. Antilysobisphosphatidic acid antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus. Clin Exp Immunol 2005; 140:173-180
130. Margutti P, Sorice M, Conti F, et al. Screening of an endothelial cDNA library identifies the C-terminal region of Nedd5 as a novel autoantigen in systemic lupus erythematosus with psychiatric manifestations. Arthritis Res Ther 2005; 7:R896-903
131. Valesini G, Alessandri C, Celestino D, et al. Anti-endothelial antibodies and neuropsychiatric systemic lupus erythematosus. Ann N Y Acad Sci 2006; 1069:118-28
132. Alessandri C, Conti F, Valesini G. Role of anti-glial fibrillary acidic protein antibodies in the pathogenesis of neuropsychiatric systemic lupus erythematosus should be clarified: comment on the article by Trysberg et al. Arthritis Rheum 2004; 50:1698-9
133. Alessandri C, Barbati C, Vacirca D, et al. T lymphocytes from patients with systemic lupus erythematosus are resistant to induction of autophagy. FASEB J. 2012 Jul 26
134. Colasanti T, Maselli A, Conti F, et al. Autoantibodies to estrogen receptor α interfere with T lymphocyte homeostasis and are associated with disease activity in systemic lupus erythematosus. Arthritis Rheum 2012; 64:778-87
135. Valesini G, Conti F. The Persistent Challenge of lupus nephritis. Clin Rev Allergy Immunol 2011; 40:135-7
136. Conti F, Ceccarelli F, Perricone C, et al. Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year follow-up study. PLoS One 2012; 7:e4593
137. Govoni M, Bombardieri S, Bortoluzzi A, et al. Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. Rheumatology Oxford 2012; 51:157-68
138. Morelli S, Bernardo ML, Viganego F, et al. Left-sided heart valve abnormalities and risk of ischemic cerebrovascular accidents in patients with systemic lupus erythematosus. Lupus 2003;12:805-812
139. Conti F, Priori R, Alessandri C, et al. Safety profile and causes of withdrawal due to adverse events in Systemic Lupus Erythematosus patients treated long-term with Cyclosporine A. Lupus 2000; 9:676-680
140. Ossandon A, Bompane D, Alessandri C, et al. Leishmania in SLE mimicking an exacerbation. Clin Exp Rheumatol 2006; 24:186-190
141. Iannuccelli C, Spinelli FR, Guzzo MP, et al. Fatigue and widespread pain in Systemic Lupus Erythematosus and Sjogren's Syndrome: symptoms of the inflammatory disease or associated Fibromyalgia? Clin Exp Rheumatol 2012; 30, Suppl 74:117-121
142. Sorice M, Pittoni V, Circella A, et al. Anti-prothrombin but not "pure" anticardiolipin antibodies are associated with the clinical features of the Antiphospholipid Antibodies Syndrome. Thromb Haemost 1998; 80:713-715
143. Caronti B, Calderaro C, Alessandri C, et al. Serum anti-β2-glycoprotein I antibodies from patients with antiphospholipid antibodies syndrome bind central nervous system. J Autoimmun 1998; 11:425-429
144. Caronti B, Calderaro C, Alessandri C, et al. Beta2-glycoprotein I, β2-GPI. mRNA is expressed by several cell types involved in antiphospholipid syndrome-related tissue damage. Clin Exp Immunol 1999; 115:214-9
145. Praticò D, Ferro D, Iuliano L, et al. Ongoing prothrombotic state in patients with antiphospholipid antibodies: a role for increased lipid peroxidation. Blood 1999; 93:3401-7
146. Ferro D, Pignatelli P, Loffredo L, et al. Soluble CD154 plasma levels in patients with systemic lupus erythematosus: modulation by antiphospholipid antibodies. Arthritis Rheum 2004; 50:1693-4
147. Priori R, Conti F, Pittoni V, et al. Is there a role for antiphospholipid-binding protein antibodies in the pathogenesis of thrombosis in Behçet's disease? Thromb Haemost 2000; 83:173-174
148. Conti F, Sorice M, Circella A, et al. Beta-2-glycoprotein I expression on monocytes is increased in anti-phospholipid antibody syndrome and correlates with tissue factor expression. Clin Exp Immunol 2003; 132:509-16
149. Alessandri C, Sorice M, Bombardieri M, et al. Antiphospholipid reactivity against cardiolipin metabolites occurring during endothelial cell apoptosis. Arthritis Res Ther 2006; 8:180
150. Conti F, Alessandri C, Perricone C, et al. Neurocognitive dysfunction in systemic lupus erythematosus: association with antiphospholipid antibodies, disease activity and chronic damage. PLoS ONE 2012; 7:e33824
151. Conti F, Ceccarelli F, Perricone C, et al. Rituximab infusionrelated adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis. Reumatology (Oxford) 2011; 50:1148-52
152. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62:222-33
153. Conti F, Perricone C, Ceccarelli F, et al. Rituximab treatment of systemic lupus arythematosus in controlled trials and in clinical practice: two sides of the same coin. Autoimmun Rev 2010; 9:716-20
154. Boyce EG, Fusco BE. Belimumab: review of use in systemic lupus erythematosus. Clin Therapeutics 2012; 5:1006-22
155. Youinou P, Devauchelle V, Huntin P, et al. A conspicuous role for B cells in Sjögren's syndrome. Clin Rev Allergy Immunol 2007; 32:231-7
156. Dörner T, Radbruch A, Burmester GR. B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol 2009; 5:433-41
157. Kawasaki A, Tsuchiya N, Fukazawa T, et al. Analysis on the association of human BLYS, BAFF, TNFSF13B. polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun 2002; 3:424-29
158. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009; 61:1168-78
159. Furie R, Petri M, Zamani O, et al. BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63:3918-30
160. Navarra SV, Guzmán RM, Gallacher AE, et al. BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:721-31
161. Pena-Rossi C, Nasonov E, Stanislav M, et al. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus 2009; 18:547-55
162. Hansen A, Lipsky PE, Dorner T. B cells in Sjogren syndrome: indication for disturbed selection and differentiation in ectopic lymphoid tissue. Arthritis Res Ter 2007; 218
163. Tedder TF, Poe JC, Haan KM. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immnol 2005; 88:1-50
164. Jacobi AM, Goldenberg DM, Hiepe F, et al. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis 2008; 67:450-57
165. Crow YJ. Type I interferonopathies: a novel set of inborn errors of immunity. Ann N Y Acad Sci 2011; 1238:91-98
166. Lichtman EI, Helfgott SM. Emerging therapies for systemic lupus erythematosus - focus on targeting interferon alpha. Clin Immunol 2012; 143:210-21
167. Merrill JT, Wallace DJ, Petri M, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody in systemic lupus erythematosus: a phase I, multicentre, double-blind randomized study. Ann Rheum Dis 2011; 70:1905-13